The estimated Net Worth of Raymond Dennis Pratt is at least $1.62 Million dollars as of 26 June 2023. Raymond Pratt owns over 6,500 units of Rockwell Medical Inc stock worth over $656,000 and over the last 12 years he sold RMTI stock worth over $0. In addition, he makes $965,874 as Chief Development Officer at Rockwell Medical Inc.
Raymond has made over 3 trades of the Rockwell Medical Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently he bought 6,500 units of RMTI stock worth $19,045 on 26 June 2023.
The largest trade he's ever made was buying 6,500 units of Rockwell Medical Inc stock on 26 June 2023 worth over $19,045. On average, Raymond trades about 833 units every 160 days since 2012. As of 26 June 2023 he still owns at least 160,000 units of Rockwell Medical Inc stock.
You can see the complete history of Raymond Pratt stock trades at the bottom of the page.
Dr. Raymond Dennis Pratt M.D. serves as Chief Development Officer of the Company., with effective 20 November 2019. has served as the Company’s Chief Development Officer since November 2019. He previously served as the Company’s Chief Medical Officer from April 2012 to November 2019. Prior to joining the Company, Dr. Pratt worked at Shire PLLC from 2003 to 2010 as vice president research and development and as the scientific leader in its Emerging Business Unit and Renal Business Unit. Previous roles at Shire included vice president global clinical medicine and global clinical affairs and head of US Clinical Development. Dr. Pratt served in a consulting role at Quintiles, a global biopharmaceutical services company, as a vice president of strategic drug development innovation from August 2011 until joining the Company, and as an industry consultant during 2011 after leaving Shire. Prior to working at Shire, he was senior director, clinical research and development at Eisai Medical Research from 1994 to 2003, where he was head of central nervous system and internal medicine clinical development. Dr. Pratt is a graduate of the University of Illinois College of Medicine and completed his nephrology fellowship at the Walter Reed Army Medical Center where he practiced nephrology and served as the assistant chief of nephrology services and director of dialysis services from 1983 to 1985. Dr. Pratt was the recipient of a physician scientist training grant at Johns Hopkins School of Medicine and the recipient of a James Shannon New Investigator award from the NIH. He served as an assistant professor in the John Hopkins Department of Medicine and Nephrology from 1989 to 1993.
As the Chief Development Officer of Rockwell Medical Inc, the total compensation of Raymond Pratt at Rockwell Medical Inc is $965,874. There are no executives at Rockwell Medical Inc getting paid more.
Raymond Pratt is 69, he's been the Chief Development Officer of Rockwell Medical Inc since 2019. There are 3 older and 13 younger executives at Rockwell Medical Inc. The oldest executive at Rockwell Medical Inc is Dr. Russell H. Ellison M.Sc., M.D., MSc., 73, who is the Pres, CEO & Director.
Raymond's mailing address filed with the SEC is 30142 Wixom Rd, Wixom, MI 48393, USA.
Over the last 21 years, insiders at Rockwell Medical Inc have traded over $3,082,721 worth of Rockwell Medical Inc stock and bought 689,891 units worth $3,959,861 . The most active insiders traders include Robert L Chioini, David S.Rbi Private Investm..., and Thomas E Klema. On average, Rockwell Medical Inc executives and independent directors trade stock every 45 days with the average trade being worth of $170,433. The most recent stock trade was executed by David S.Rbi Private Investm... on 21 December 2020, trading 42,450 units of RMTI stock currently worth $43,724.
rockwell medical is a fully-integrated biopharmaceutical company targeting end-stage renal disease (esrd) and chronic kidney disease (ckd) with innovative products and services for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis. rockwell’s new innovative therapy triferic is the only fda approved drug indicated to replace iron and maintain hemoglobin in hemodialysis patients suffering from anemia. via dialysate during each dialysis treatment, triferic replaces the 5-7 mg iron loss that occurs in all patients, maintaining their iron balance. unlike iv iron products, triferic binds iron immediately and completely to transferrin (carrier of iron in the body) upon entering the blood and is then transported directly to the bone marrow to be incorporated into hemoglobin, with no increase in ferritin (stored iron and inflammation) and no anaphylaxis, addressing a significant unmet need in overcoming functional iron deficiency (fid) in esrd patients. visit www
Rockwell Medical Inc executives and other stock owners filed with the SEC include: